Intravenous Lacosamide Effective Against Pediatric Cluster Seizures: Study

The key findings of this study were:

The median age at epilepsy onset was 1.5 years. Also, the patients underwent an average of five seizures within a 12-hour period. The majority of patients (17 out of 25) had remote etiologies, with focal motor seizures being the most common type.

Out of the 25 patients, 48% patients responded positively to intravenous lacosamide by achieving seizure freedom. Also, 52.9% of patients who received lacosamide as a first-line therapy underwent complete seizure remission.

The patients with remote etiologies had a higher response rate, where 58.8% patients achieved complete seizure freedom. Among these, children with structural abnormalities expressed a notable 58.3% remission rate. Also, no adverse events were reported which highlighted the safety of lacosamide in this pediatric population.

The high remission rates, especially among the individuals with remote etiologies and structural abnormalities are particularly promising. These results could pave the way for more extensive clinical trials and based on the critical findings of this study, Intravenous lacosamide therapy may be considered as a potential therapeutic option for the children with cluster seizures.

Source:

Matsuura, R., Hamano, S., Kikuchi, K., Takeda, R., Takeuchi, H., Hirata, Y., Koichihara, R., Niitsu, T., Ueta, I., & Oka, A. (2024). Intravenous Lacosamide Therapy for Pediatric Patients With Cluster Seizures. In Pediatric Neurology (Vol. 157, pp. 1–4). Elsevier BV. https://doi.org/10.1016/j.pediatrneurol.2024.05.003